Expired activity
Please go to the PowerPak homepage and select a course.

Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients (Solid Organ and Stem Cell): What Pharmacists Need to Know

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Merck.


Darrell T. Hulisz, RPh, PharmD
Associate Professor
Department of Family Medicine & Community Health
Case Western Reserve University, School of Medicine
University Hospitals Medical Group
Cleveland, OH

Medical Writer
Katherine Wandersee
Freelance Medical Writer
Montclair, NJ


Darrell T. Hulisz, RPh, PharmD has no actual or potential conflicts of interest in relation to this educational activity.

Katherine Wandersee has no actual or potential conflicts of interest in relation to this educational activity.

The clinical reviewer, Steven Kheloussi, PharmD, has no actual or potential conflicts of interest in relation to this educational activity.

Susanne Batesko, RN, BSN, Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-20-116-H01-P
Credits: 2.0 hour (0.2 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes


September 30, 2020


September 30, 2021


This accredited activity has been designed for pharmacists.


During the period September 30, 2020 to September 30, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. Your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To update hospital pharmacists on the prevention and management of CMV in high-risk patient groups, including those who are severely immunosuppressed or undergoing procedures such as allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT).


Upon completion of this educational activity, participants should be better able to:

  • Describe patient populations and procedures associated with the greatest risk for negative outcomes due to CMV infection or reactivation.
  • Review recent guideline statements and expert recommendations for CMV infection management, prevention, and follow-up care.
  • Assess current data on new/novel treatment and prevention approaches targeted toward CMV.
  • Discuss the hospital pharmacist's role in the treatment and prevention of infection from CMV.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Merck. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.